Prab: CSV import

2024-03-06T04:56:49Z

CSV import

New page

[[File:Almokalant.png|thumb|{{PAGENAME}}]]<br>'''Almokalant''' is a [[Class III antiarrhythmic agent]] used in the treatment of [[cardiac arrhythmia]]. It is a [[potassium channel blocker]] that prolongs the duration of the [[action potential]], thereby lengthening the [[refractory period]].

==Pharmacology==
[[Almokalant]] works by blocking the [[rapid component of the delayed rectifier potassium current]] (I<sub>Kr</sub>) in the [[cardiac myocyte]]. This action prolongs the duration of the [[action potential]] and refractory period, which can help to prevent the re-entry of electrical impulses that can cause [[arrhythmia]].

==Clinical Use==
[[Almokalant]] is used in the treatment of various types of [[cardiac arrhythmia]], including [[atrial fibrillation]] and [[atrial flutter]]. It can be used alone or in combination with other [[antiarrhythmic drugs]].

==Side Effects==
Like other [[Class III antiarrhythmic agents]], [[Almokalant]] can cause [[proarrhythmia]], a condition where the drug can actually cause new or worsening arrhythmias. Other potential side effects include [[nausea]], [[vomiting]], and [[diarrhea]].

==History==
[[Almokalant]] was first synthesized in the 1980s and has been used in clinical practice since the 1990s. It was originally developed by the Swedish pharmaceutical company [[AstraZeneca]].

==See Also==
* [[Antiarrhythmic agent]]
* [[Potassium channel blocker]]
* [[Cardiac arrhythmia]]
* [[Atrial fibrillation]]
* [[AstraZeneca]]

[[Category:Antiarrhythmic agents]]
[[Category:Potassium channel blockers]]
[[Category:Drugs]]
{{pharmacology-stub}}

Almokalant - Revision history

Prab: CSV import